Breast Cancer Gene Expression Signatures: Development and Clinical Significance-a Narrative Review

Overview

Journal Transl Breast Cancer Res

Publisher AME Publishing Company

Date 2024 May 16

PMID 38751471

Authors

Siyan Li

Xinmiao Yu

Yingying Xu

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Breast cancer gene expression signatures are developing rapidly and are expected to better understand the intrinsic features of the tumor, and also to optimize the treatment strategy in clinical practice. This review is to summarize the controversy and consensus in clinical practice of gene expression signatures, and to provide our perspective on these issues as well as recommendation for future direction.

Methods: We reviewed English publications in PubMed related to breast cancer gene expression signatures from 2002 to 2022.

Key Content And Findings: Five mature commercial gene expression signatures: Oncotype, MammaPrint, Prosigna/PAM50, EndoPredict and Breast Cancer Index (BCI) are available to provide the prognostic and predictive assessment. Although they could help to evaluate the risk of recurrence and to predict the benefits of certain treatments, their applications remain challenging. Treatment decisions should be determined by a combination of related clinical pathological factors in clinical practice.

Conclusions: Gene expression signatures could assist in the determination of the adjuvant therapy of early-stage breast cancer. The prospective randomized clinical trials showed that chemotherapy may be exempted in low-risk patients. More sufficient data are expected for the application in radiotherapy, extended endocrine therapy, and neoadjuvant treatment. The treatment cannot be determined by a single factor but by comprehensive assessments of clinicopathological factors, test purpose, and cost-effectiveness. Patients will benefit from personalized treatments with the publication of further evidence.

References

Speers C, Zhao S, Liu M, Bartelink H, Pierce L, Feng F . Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. Clin Cancer Res. 2015; 21(16):3667-77. DOI: 10.1158/1078-0432.CCR-14-2898. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

Petkov V, Miller D, Howlader N, Gliner N, Howe W, Schussler N . Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2017; 2:16017. PMC: 5515329. DOI: 10.1038/npjbcancer.2016.17. View

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P . Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the.... J Clin Oncol. 2014; 33(8):916-22. DOI: 10.1200/JCO.2014.55.6894. View

Bartlett J, Sgroi D, Treuner K, Zhang Y, Ahmed I, Piper T . Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019; 30(11):1776-1783. PMC: 6927322. DOI: 10.1093/annonc/mdz289. View

Sgroi D, Sestak I, Cuzick J, Zhang Y, Schnabel C, Schroeder B . Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013; 14(11):1067-1076. PMC: 3918681. DOI: 10.1016/S1470-2045(13)70387-5. View

Hoskins K, Danciu O, Ko N, Calip G . Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women. JAMA Oncol. 2021; 7(3):370-378. PMC: 7821091. DOI: 10.1001/jamaoncol.2020.7320. View

Buus R, Sestak I, Kronenwett R, Ferree S, Schnabel C, Baehner F . Molecular Drivers of Onco DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. J Clin Oncol. 2020; 39(2):126-135. PMC: 8078458. DOI: 10.1200/JCO.20.00853. View

10.

Tarighati E, Keivan H, Mahani H . A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med. 2022; 23(1):1-16. DOI: 10.1007/s10238-021-00781-1. View

11.

McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935):2127-35. PMC: 5015598. DOI: 10.1016/S0140-6736(14)60488-8. View

12.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens J . Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2013; 105(19):1504-11. PMC: 3787911. DOI: 10.1093/jnci/djt244. View

13.

Solin L, Gray R, Baehner F, Butler S, Hughes L, Yoshizawa C . A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013; 105(10):701-10. PMC: 3653823. DOI: 10.1093/jnci/djt067. View

14.

Lopes Cardozo J, Drukker C, Rutgers E, Schmidt M, Glas A, Witteveen A . Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. J Clin Oncol. 2022; 40(12):1335-1345. DOI: 10.1200/JCO.21.02019. View

15.

Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E . Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clin Cancer Res. 2020; 27(1):311-319. DOI: 10.1158/1078-0432.CCR-20-2737. View

16.

Olivotto I, Bajdik C, Ravdin P, Speers C, Coldman A, Norris B . Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005; 23(12):2716-25. DOI: 10.1200/JCO.2005.06.178. View

17.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

18.

Cheng S, Huang T, Cheng Y, Tan T, Horng C, Wang Y . Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer. PLoS One. 2017; 12(9):e0184372. PMC: 5590926. DOI: 10.1371/journal.pone.0184372. View

19.

Kalinsky K, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D . 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021; 385(25):2336-2347. PMC: 9096864. DOI: 10.1056/NEJMoa2108873. View

20.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View